{"classes":[{"categories":[{"measurements":[{"comment":"Upper limit not reached","groupId":"OG000","lowerLimit":"11.4","upperLimit":"NA","value":"53.6"},{"groupId":"OG001","lowerLimit":"0.6","upperLimit":"8.4","value":"4.9"},{"groupId":"OG002","lowerLimit":"0.4","upperLimit":"1.6","value":"1.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"24"}],"units":"Participants"}],"description":"Time in months from 1st first dose until progression (resistance or refractory disease) or death was first documented by investigator. Progressive disease: Resistant disease for which investigator may electively stop treatment or refractory disease requiring cessation of study treatment. The PFS was estimated using the Kaplan-Meier product-limit method, and a two-sided 95% CI for the median PFS time was computed using the method of Brookmeyer and Crowley.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with imatinib-resistant Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (CP). Starting Dose Level of 60 mg/m\\^2; Escalated/Dose Level 2 of 80 mg/m\\^2. QD, as long as clinical benefit was maintained.","id":"OG000","title":"Stratum1 Ph+ CP-CML; Dasatinib 60 mg/m^2 Starting Dose"},{"description":"Participants with imatinib-resistant or imatinib-intolerant Ph+ CML in accelerated phase (AP), or in myeloid blast phase (MBP), or in lymphoid blast phase (LBP); or relapsed or refractory Ph+ acute lymphoblastic leukemia (ALL) after imatinib use; or second or subsequent relapse of Ph+ acute myeloid leukemia (AML). Starting Dose Level of 60 mg/m\\^2; Escalated/Dose level 2 of 80 mg/m\\^2. QD, as long as clinical benefit was maintained.","id":"OG001","title":"Stratum2/3 Ph+ALL or AP/BP-CML;Dasatinib60mg/m^2 Starting Dose"},{"description":"Participants with second or subsequent relapse of Ph- ALL or Ph- AML. Starting Dose Level of 60 mg/m\\^2; Escalated/Dose level 2 of 80 mg/m\\^2, Escalated/Dose level 3 of 100 mg/m\\^2, and Escalated/Dose level 4 of 120 mg/m\\^2. QD, as long as clinical benefit was maintained.","id":"OG002","title":"Stratum4 Ph- ALL/AML; Dasatinib 60 mg/m^2 Starting Dose"}],"paramType":"MEDIAN","populationDescription":"All treated participants: Participants who received at least 1 dose of study therapy. If no progression or death was reported, PFS was censored at the last assessment date done on-study (i.e., up to 30 days after last dosing date) at which non-progression was reported.","reportingStatus":"POSTED","timeFrame":"From the date of randomization to date of progression, death, last tumor assessment, or 5 years after EOT (Median duration of therapy in months: Stratum 1=24.11 [Range: 2.27-50.63]; Stratum 2/3=3.02 [Range: 0.53-37.72]; Stratum 4=1.14 [Range: 0.03-3.38])","title":"Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}